---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-009014"
form_type: "8-K"
ticker: "PACB"
cik: "0001299130"
company_name: "PACIFIC BIOSCIENCES OF CALIFORNIA, INC."
filed_at: "2026-02-02T23:59:59+00:00"
generated_at: "2026-05-16T05:33:46.600553+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PacBio completes sale of short-read sequencing assets to Illumina for $48.1M net cash

## Summary
- Sold certain short-read DNA sequencing IP and related technologies to Illumina for $50M gross; net cash proceeds $48.1M.
- Illumina assumed certain liabilities and granted PacBio a non-exclusive license back to certain IP.
- Transaction closed Jan 30, 2026; company to focus on long-read sequencing and accelerate SPRQ-Nx chemistry launch.
- Proceeds strengthen balance sheet; $1.9M paid to former Apton equity holders to waive milestone obligations.

## SEC filing metadata
- accession: 0001104659-26-009014
- form_type: 8-K
- ticker: PACB
- cik: 0001299130
- company_name: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
- filed_at: 2026-02-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1299130/000110465926009014/0001104659-26-009014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1299130/000110465926009014/tm264755d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-009014
- JSON: https://secwatch.observer/filing/0001104659-26-009014.json
- Plain text: https://secwatch.observer/filing/0001104659-26-009014.txt

## Source-grounded claims
- claim_id: 6d2550be8d109b47446a9226c7a1fbab0da8ed11
  claim: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. completed a disposition involving Illumina Cambridge Limited for $50.0 million in cash (closed 2026-01-30).
  evidence_excerpt: On January 30, 2026, Pacific Biosciences of California, Inc. (the “Company”) completed the disposition of assets to Illumina Cambridge Limited (the “Buyer”) in accordance with the terms of an Asset Purchase Agreement, dated January 30, 2026 (the “Asset Purchase Agreement”), by and between the Company, the Buyer, and Illumina, Inc., solely for purposes of Section 8.16 of the Asset Purchase Agreement, pursuant to which, among other matters, the Buyer acquired certain intellectual property and other assets related to the Company’s short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies (the “Asset Sale”). As consideration for the Asset Sale, the Buyer paid the Company $50.0 million in cash and assumed certain liabilities (the “Purchase Price”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1299130/000110465926009014/0001104659-26-009014-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.